

Evonik features scientifically crafted CBD system solutions at NYSCC Suppliers' Day

- New approach to cannabidiol solutions for skin care
- First in a family of CBD solutions
- Available in U.S. market

Essen, Germany. Evonik is unveiling its TEGO® CBD Revitalize system solutions at the New York Society of Cosmetic Chemists' Suppliers' Day event at the Jacob Javitz Center in New York City on 3–4 May. This new product leverages cannabidiol (CBD) along with other synergistic components to enable formulators to provide skin revitalization benefits to their consumers. TEGO® CBD Revitalize will initially be offered in the U.S. market, with plans for availability in other regions later this year.

Unlike CBD-based solutions which rely either on CBD itself or on the natural cocktail of constituents that accompany CBD, TEGO® CBD Revitalize brings together a highly purified CBD with scientifically selected components to offer a claims-focused, tailored solution for the market. In this fashion, brands can enjoy specific and differentiated product claims using CBD, without regulatory-related concerns that can emerge from some constituents found in the extract's natural cocktail.

“We are excited to launch TEGO® CBD Revitalize and help evolve the CBD beauty market to deliver even better on claims and meet consumer needs,” says Arnaldo Fonseca, global head of the BioActives segment in Evonik's Care Solutions business line.

Evonik's SimDerma® technology, which underpins the scientific construction of the product, was first presented at a podium presentation at the 2021 International Federation of Society of Cosmetic Chemists' meeting. This technology enables Evonik scientists to design synergistic blends, where collective benefits outperform those of individual components. Further information about TEGO® CBD Revitalize's synergistic performance was provided through a poster at the 2021 U.S. Society of Cosmetic Chemists' Annual Meeting in December. Customers can now learn more about and request samples of the material for evaluation.

2 May 2022

Main press contact

Jana Flommersfeld

Head of Market Communications
Care Solutions business line
Phone + 49 2011 73-3772
jana.flommersfeld@evonik.com

Alternative press contact

Dr. Jürgen Krauter

Head of Market Communications Evonik
Phone +49 6181 59-6847
juergen.krauter@evonik.com

Evonik Industries AG

Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
www.evonik.com

Supervisory Board

Bernd Tönjes, Chairman

Executive Board

Christian Kullmann, Chairman

Dr. Harald Schwager, Deputy Chairman

Thomas Wessel, Ute Wolf

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

Further information

Formulators attending NYSCC Suppliers' Day are encouraged to visit Evonik's booth 1301 to learn more.

Additional product information is available at the firm's intobeauty.evonik.com and at personal-care.evonik.com/en/events/nyscc-2022.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.